Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1–2% of all thyroid
cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC …

In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13
locus and/or mutation (s) within the TP53 gene, are associated with resistance to …

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in
terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is …

The human TP53 locus, located on the short arm of chromosome 17, encodes a tumour
suppressor protein which functions as a tetrameric transcription factor capable of regulating …

Sarcomas include diverse mesenchymal neoplasms with widely varied prognosis, clinical
behavior, and treatment. Owing to their rarity and histologic overlap, accurate diagnosis of …

The tumor suppressive transcription factor p53 regulates a wide array of cellular processes
that confer upon cells an essential protection against cancer development. Wild-type p53 …

p53, first described four decades ago, is now established as a master regulator of cellular
stress response, the “guardian of the genome”. p53 contributes to biological robustness by …

Abstract Li–Fraumeni syndrome (LFS), caused by the germline mutations in the TP53 gene,
leads to significant lifetime risk to cancer in the central nervous system. Recognition of LFS …

Background Mutations of the tumour-suppressor gene TP53 are the most frequent somatic
genomic alterations in head and neck squamous cell carcinoma (HNSCC). However, it is not …

Infrequent and rare genetic variants in the human population vastly outnumber common
ones. Although they may contribute significantly to the genetic basis of a disease, these …